D.E. Shaw & Co’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-823,251
| Closed | -$49.3M | – | 4468 |
|
|
2019
Q4 | $49.3M | Buy |
823,251
+91,349
| +12% | +$3.43M | 0.06% | 394 |
|
|
2019
Q3 | $20.6M | Buy |
731,902
+138,955
| +23% | +$4.74M | 0.03% | 766 |
|
|
2019
Q2 | $22.4M | Buy |
592,947
+321,756
| +119% | +$12.4M | 0.03% | 693 |
|
|
2019
Q1 | $10.6M | Buy |
271,191
+131,550
| +94% | +$3.77M | 0.01% | 1071 |
|
|
2018
Q4 | $2.98M | Buy |
139,641
+74,529
| +114% | +$1.92M | ﹤0.01% | 1861 |
|
|
2018
Q3 | $2.58M | Sell |
65,112
-14,419
| -18% | -$537K | ﹤0.01% | 2023 |
|
|
2018
Q2 | $3.04M | Buy |
79,531
+40,194
| +102% | +$1.49M | ﹤0.01% | 1913 |
|
|
2018
Q1 | $1.18M | Buy |
39,337
+17,221
| +78% | +$583K | ﹤0.01% | 2380 |
|
|
2017
Q4 | $691K | Sell |
22,116
-43,236
| -66% | -$1.19M | ﹤0.01% | 2783 |
|
|
2017
Q3 | $1.83M | Sell |
65,352
-2,174
| -3% | -$47.2K | ﹤0.01% | 2099 |
|
|
2017
Q2 | $1.29M | Buy |
67,526
+33,584
| +99% | +$536K | ﹤0.01% | 2253 |
|
|
2017
Q1 | $578K | Buy |
33,942
+13,934
| +70% | +$225K | ﹤0.01% | 2654 |
|
|
2016
Q4 | $366K | Sell |
20,008
-12,862
| -39% | -$222K | ﹤0.01% | 3025 |
|
|
2016
Q3 | $585K | Buy |
+32,870
| New | +$499K | ﹤0.01% | 2714 |
|
D.E. Shaw & Co's BOLD Position: Q1 2020 in Review
D.E. Shaw & Co sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 823,251 shares — an estimated $49.3M sold.
D.E. Shaw & Co first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $49.3M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- D.E. Shaw & Co reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- D.E. Shaw & Co sold 823,251 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $49.3M.
- D.E. Shaw & Co first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- D.E. Shaw & Co's Audentes Therapeutics, Inc position peaked at $49.3M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on D.E. Shaw & Co's 13F filing for Q1 2020, filed 15 May 2020.